MARK HONZEL: Open Payments
NPI 1083761670 · BEVERLY HILLS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,231 in 212 payments from 28 companies in 2025. Trend: 2023 $4,162 · 2024 $4,821 · 2025 $5,231
Food & beverage: $5,231
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $689 |
| Vanda Pharmaceuticals Inc. | 26 | $589 |
| Axsome Therapeutics, Inc. | 27 | $553 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $460 |
| ViiV Healthcare Company | 15 | $421 |
| Indivior Inc. | 12 | $330 |
| Lundbeck LLC | 14 | $326 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 15 | $308 |
| Gilead Sciences, Inc. | 8 | $221 |
| Alkermes, Inc. | 7 | $219 |
Products named: VRAYLAR, FANAPT, CAPLYTA, Auvelity, REXULTI, SUBLOCADE, RELISTOR, ARISTADA.
Industry payments across CA — which companies pay providers there.
